OncoCyte Corp
(LTS:0KCC)
$
3.03
0 (0%)
Market Cap: 44.91 Mil
Enterprise Value: 42.66 Mil
PE Ratio: 0
PB Ratio: 2.40
GF Score: 30/100 OncoCyte Corp (LTS:0KCC) Transcripts
- Q1 2024 OncoCyte Corp Earnings Call TranscriptMay 15, 2024$2.88Earnings
- Q4 2023 OncoCyte Corp Earnings Call TranscriptApr 12, 2024$4.96 (+62.09%)Earnings
- Q3 2023 OncoCyte Corp Earnings Call TranscriptNov 09, 2023$2.55 (+10.15%)Earnings
- Q2 2023 OncoCyte Corp Earnings Call TranscriptAug 10, 2023$3.85Earnings
- OncoCyte Corp Extraordinary Shareholders Meeting TranscriptJul 24, 2023
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 23, 2023
- Q1 2023 OncoCyte Corp Earnings Call TranscriptMay 11, 2023$5.28Earnings
- Q4 2022 OncoCyte Corp Earnings Call TranscriptApr 03, 2023$5.2Earnings
- Q3 2022 OncoCyte Corp Earnings Call TranscriptNov 10, 2022$13.56Earnings
- OncoCyte Corp at UBS Genomics 2.0 and MedTech Innovations Summit TranscriptAug 11, 2022
- Q2 2022 OncoCyte Corp Earnings Call TranscriptAug 10, 2022$17.17 (-5.39%)Earnings
- OncoCyte Corp DetermalO™ and Tumor Microenvironment in Clinical Practice Key Opinion Leader TranscriptJun 28, 2022
- Q1 2022 OncoCyte Corp Earnings Call TranscriptMay 11, 2022$22.8Earnings
- Q4 2021 OncoCyte Corp Earnings Call TranscriptMar 10, 2022$34.4Earnings
- OncoCyte Corp to Discuss Development and Co-Marketing Agreement with Thermo Fisher Scientific Inc Call TranscriptJan 18, 2022
- OncoCyte Corp Investor and Analyst Day TranscriptDec 14, 2021
- Q3 2021 OncoCyte Corp Earnings Call TranscriptNov 09, 2021$69.9 (+2.75%)Earnings
- OncoCyte Corp Key Opinion Leader Presentation Part 2: DetermaIO™ in Triple-Negative Breast Cancer TranscriptSep 28, 2021
- OncoCyte Corp Key Opinion Leader Presentation Part 1: Transplant Rejection Testing TranscriptSep 22, 2021
- Q2 2021 OncoCyte Corp Earnings Call TranscriptAug 10, 2021$102Earnings
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 24, 2021
- Q1 2021 OncoCyte Corp Earnings Call TranscriptMay 17, 2021$79.4Earnings
- OncoCyte Corp DetermaIO™ Data KOL Webinar TranscriptApr 19, 2021
- Q4 2020 OncoCyte Corp Earnings Call TranscriptMar 16, 2021$96.76 (-0.04%)Earnings
- Q3 2020 OncoCyte Corp Earnings Call TranscriptNov 12, 2020$26.2Earnings
- OncoCyte Corp - EGFR And Molecular Risk Stratification In Early-Stage NSCLC TranscriptOct 22, 2020
- OncoCyte Corporation - Special Call TranscriptAug 19, 2020
- Q2 2020 OncoCyte Corp Earnings Call TranscriptJul 29, 2020$26.2Earnings
- OncoCyte Corp Announces Completion Of Determadx™ Clinical Validation Study TranscriptJun 29, 2020
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 17, 2020
- Q1 2020 OncoCyte Corp Earnings Call TranscriptMay 12, 2020$46.56Earnings
- Q4 2019 OncoCyte Corp Earnings Call TranscriptMar 25, 2020$46.56Earnings
- OncoCyte Corp to Acquire Insight Genetics Inc - Conference Call TranscriptJan 10, 2020
- Q3 2019 OncoCyte Corp Earnings Call TranscriptNov 14, 2019$40Earnings
- Q2 2019 OncoCyte Corp Earnings Call TranscriptAug 14, 2019$40Earnings
- 1